"About a month after my treatment their was no white spots", page-39

Interesting that Paul talked up the Zilosul-specific IP in that interview, and Paradigm having a role in it. I'm behind that kind of talk, even if it is just talk. Possibly just a tactic to create some perception, because yeah, turning the API into an injectible solution (which is done by a contractor anyway, as per the same interview) is scant additional IP at best - but, put simply, Zilosul can't be Zilosul without it coming through PAR, and it will be Zilosul, and Zilosul alone, which will get regulatory approval (including 3-year regulatory exclusivity) if/when it is approved.

I still reckon you'd need to be a bit of a loose unit to inject a product which is only approved for horses. With due respect to @adherent and @greedymerchant of course lol

The vast majority of people - especially in the major and most well-regulated Pharma markets - won't consider this once a product approved for humans is available.